Search
Metenkefalin
go.drugbank.com/drugs/DB12668InvestigationalMetenkefalin is an endogenous opioid and beta-endorphin.[A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. … [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]
LS11
go.drugbank.com/drugs/DB05918InvestigationalLS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death.
Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells
go.drugbank.com/drugs/DB28348Approved[L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning … in adult patients for whom a suitable donor is not available.
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively.
Chlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Dengue virus serotype 2
go.drugbank.com/drugs/DB22665Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Dengue virus serotype 3
go.drugbank.com/drugs/DB22666Approved[L53368] Qdenga was approved for use in the European Union in December 2022.[L53373]
Amolimogene bepiplasmid
go.drugbank.com/drugs/DB04904InvestigationalAmolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia. … Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV).
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalIn preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. … Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.